Question 1

What is Antharis Therapeutics?

Accepted Answer

Antharis Therapeutics is a Entity.

Question 2

How often does Antharis Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Antharis Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jun 15, 2026.

Question 4

When was Antharis Therapeutics last mentioned in news?

Accepted Answer

Last active on Jun 18, 2026.

Question 5

What is Antharis Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Antharis Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Antharis Therapeutics?

Accepted Answer

Lonza Licenses ADC Tech to Antharis (Jun 15, 2026, 6 articles).

Question 8

How did the "Lonza Licenses ADC Tech to Antharis" event impact Antharis Therapeutics?

Accepted Answer

Antharis Therapeutics has secured an exclusive, target-specific licensing agreement with Lonza Group to develop novel dual-payload ADCs for gastrointestinal cancers. This agreement allows Antharis Therapeutics to integrate Lonza Group's clinically validated technology with its own expertise, advancing its lead ADC program into clinical trials and strengthening its position in oncology drug development.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.